These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer. van der Meijden AP Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591 [No Abstract] [Full Text] [Related]
11. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
12. [Nonspecific immunotherapy with BCG vaccine in bladder tumors]. Damianov Kh; Patrashkov T; Petkov Ts; Tonchev T; Petrov P Khirurgiia (Sofiia); 1990; 43(1):48-53. PubMed ID: 2395285 [TBL] [Abstract][Full Text] [Related]
13. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
14. The management of superficial bladder cancer. Dalbagni G Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810 [TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of superficial bladder tumors in a hospital department]. Prekopp G; Rosdy E Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124 [TBL] [Abstract][Full Text] [Related]
17. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905 [TBL] [Abstract][Full Text] [Related]
18. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related]
19. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence]. Korovin AI; Savvin VT Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034 [TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]